In contrast, IL15 super-antagonist (IL15SA) in combination with imatinib significantly restored intratumoural effector CD8+ T cell function and intracellular PI3K signalling in CD8+ T cells, thereby enhancing tumour killing (87). Here, CD8A is linked to neoplasm.